Chronic Lymphocytic Leukemia

• FDA label_change · 2024-06-04
  FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)

  FDA approved a supplemental application for BRUKINSA (zanubrutinib) to update the product labeling.

• FDA label_change · 2022-06-30
  FDA Approved: LENALIDOMIDE — Supplemental Application (Dr. Reddy's Laboratories Inc.)

  FDA approved a supplemental application for lenalidomide submitted by Dr. Reddy's Laboratories Inc., resulting in updated labeling for the d…

• FDA label_change · 2019-10-08
  FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) by Teva Pharmaceuticals to update its labeling.

• FDA label_change · 2017-06-22
  FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)

  FDA approved a supplemental application for Rituxan Hycela (rituximab and hyaluronidase) by Genentech, updating the labeling for this subcut…

• FDA label_change · 2011-10-28
  FDA Approved: LEUKERAN — Supplemental Application (Waylis Therapeutics LLC)

  FDA supplemental application for Leukeran (chlorambucil) submitted by Waylis Therapeutics LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.